报价延迟最少15分钟:2026/04/29 02:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8771 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.42/-0.30
|
|
企业价值
109.84M
|
| 资产负债 |
|
每股账面净值
1.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
33.03M
|
|
每股收益
0.38
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use. |
